Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
100 participants
INTERVENTIONAL
2012-05-31
2018-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1
NCT02211768
PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)
NCT01800032
Multi-parametric Biomarker Development to Predict Malignant Conversion in Patients With Neurofibromatosis Type 1
NCT05677594
Study of the Capacity of the MRI Spectroscopy to Define the Tumor Area Enriched in Glioblastoma Stem Cells. Proof of Concept Study
NCT01872221
FArial NErf MRI in the Preoperative Assessment of PArotide Tumors
NCT04613349
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Initial monitoring group
MRI
MRI every 3 months during the first year and then every 6 months during the second year and then one MRI up to 36 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MRI
MRI every 3 months during the first year and then every 6 months during the second year and then one MRI up to 36 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adults patients
* Peripheral primitive fibromatosis proved by biopsy
* Peripheral primitive fibromatosis R2 resected for which monitoring is decided
* MRI realized before inclusion
* Patient information and informed consent signed
Exclusion Criteria
* Head and neck topography
* Primitive fibromatosis R0 or R1 resected
* Specific medical treatment of fibromatosis
* Patient already included in an other clinical trial with an experimental molecule
* Persons deprived of liberty
* Impossibility to submit to the trial's medical follow-up for psychological, geographical or socials reasons
* Previous history of cancer
* Counter indication to the realization of an MRI
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gustave Roussy, Cancer Campus, Grand Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institut Gustave Roussy
Villejuif, Val de Marne, France
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2011/1774
Identifier Type: OTHER
Identifier Source: secondary_id
2011-A01188-33
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.